15 drugs added to Medicare price negotiations
Boxes of the drug trulicity, made by Eli Lilly and Company, sit on a counter at a pharmacy…
Next steps for Eli Lilly, Novo Nordisk, Pfizer
A pharmacist displays a box of Wegovy pills at a pharmacy in Provo, Utah, Jan. 15, 2026. George…
Another alliance of health care and AI signals why pharma stocks could be back
Bristol Myers Squibb and Microsoft ‘s new partnership aimed at accelerating early detection of lung cancer marks the…
Novo Nordisk shares rise after Wegovy obesity pill launch
A pharmacist displays a box of Wegovy pills at a pharmacy in Provo, Utah, US, on Thursday, Jan.…
First GLP-1 pill for obesity from Novo Nordisk launches in the U.S.
The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, on the…
Novo Nordisk beyond weight loss has investors wary, scientists hopeful
Ozempic is medicine for adults with type 2 diabetes that along with diet and exercise may improve blood…
Johnson & Johnson halts mid-stage trial of experimental eczema drug
Johnson & Johnson offices in Irvine, California, US, on Friday, Oct. 10, 2025. Kyle Grillot | Bloomberg |…
Eli Lilly investors shouldn’t sweat rival Novo Nordisk having the first obesity pill on sale
Jim Cramer says don’t sweat Novo Nordisk’s head start over Club holding Eli Lilly in the obesity pill…
Obesity pills from Novo Nordisk, Eli Lilly are coming
Daniel Grill | Tetra Images | Getty Images A version of this article first appeared in CNBC’s Healthy…
Eli Lilly’s weight loss drug retatrutide clears first late-stage study
The Eli Lilly logo appears on the company’s office in San Diego, California, U.S., Nov. 21, 2025. Mike…
WHO backs use of GLP-1 therapies for obesity, warns access will remain limited
A view shows The World Health Organization (WHO) headquarters in Geneva, Switzerland, Jan. 28, 2025. Denis Balibouse |…
Novo Nordisk stumbles against Eli Lilly in GLP-1 drug battle. Which stock is best?
In the battle between weight-loss drug companies, Eli Lilly has emerged as the clear winner for investors. The…